Welcome to our dedicated page for Moderna news (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna stock.
Moderna (MRNA) remains at the forefront of mRNA technology innovation, developing transformative therapies for infectious diseases, oncology, and rare conditions. This dedicated news hub provides investors and healthcare professionals with essential updates directly from the company and verified sources.
Access official press releases covering clinical trial results, regulatory milestones, and strategic partnerships, alongside analysis of quarterly earnings and pipeline developments. Our curated collection ensures you stay informed about Moderna's progress in advancing mRNA-based medicines without promotional bias.
Key updates include developments in respiratory vaccines, cancer immunotherapy candidates, and rare disease treatments. Bookmark this page for real-time access to Moderna's verified announcements and objective reporting on one of biotechnology's most innovative platforms.
Moderna (Nasdaq: MRNA) has announced new funding commitments to enhance manufacturing capabilities, aiming to increase its global COVID-19 vaccine supply to up to 3 billion doses in 2022. This capacity boost involves doubling production at Lonza in Switzerland and over doubling at Rovi in Spain. The company is also in advanced negotiations for further agreements. Moderna expects heightened demand for vaccines due to the emergence of variants and waning immunity. The company aims to enhance its vaccine's shelf life and is actively developing new formulations.
DNA Script announced a partnership with Moderna (MRNA) to develop a prototype for mobile vaccine and therapeutic manufacturing under DARPA's Nucleic Acids On-Demand World-Wide Program. This collaboration will utilize DNA Script's enzymatic synthesis platform to produce high-fidelity nucleic acids, enhancing Moderna's mRNA technology. DNA Script will receive up to $5 million in grant funding from DARPA. The initiative aims to create mobile units for rapid production of mRNA vaccines, potentially offering immediate medical responses to pathogen threats.
Moderna (Nasdaq: MRNA) has signed an agreement with Sanofi (Nasdaq: SNY) for fill/finish sterile manufacturing and packaging of up to 200 million doses of the Moderna COVID-19 Vaccine in the U.S., starting September 2021. This partnership aims to enhance production capacity, with Sanofi utilizing its manufacturing site in Ridgefield, NJ. Juan Andres, Moderna’s Chief Technical Operations and Quality Officer, expressed gratitude to the Department of Health and Human Services and the Biden Administration for facilitating this collaboration, emphasizing its importance for scaling up vaccine supply.
Moderna, Inc. (Nasdaq: MRNA) announced a new supply agreement with Israel for 2022, allowing Israel to purchase doses of Moderna's COVID-19 vaccine and a variant-specific vaccine pending regulatory approval. This follows two previous agreements totaling 10 million doses. CEO Stéphane Bancel emphasized the significance of this agreement as a milestone for 2022 supply and ongoing clinical trials for variant-specific boosters, which have shown promising preclinical efficacy against COVID-19 variants.
Moderna, Inc. (Nasdaq: MRNA) will host a live conference call on May 6, 2021, at 8:00 a.m. ET to report its Q1 2021 financial results and provide a corporate update. Investors can join by dialing 866-922-5184 (domestic) or 409-937-8950 (international) with conference ID 7487119. The call will also be webcast and archived on Moderna’s investor website for a year. Over the past ten years, Moderna has evolved significantly, developing a diverse portfolio of vaccines and therapeutics, including one of the earliest COVID-19 vaccines, thanks to its advanced mRNA technology.
Moderna (Nasdaq: MRNA) hosted its second annual Vaccines Day, showcasing its mRNA vaccine capabilities. The company revealed new positive interim Phase 1 data for its Respiratory Syncytial Virus (RSV) vaccine candidate (mRNA-1345) and interim Phase 2 data for its cytomegalovirus (CMV) candidate. Moderna aims to leverage its mRNA platform to accelerate vaccine development, addressing the significant gap in available vaccines for many human viruses. The Phase 1 analysis indicates mRNA-1345 is well-tolerated, with no severe adverse events reported, furthering Moderna's innovative vaccine pipeline.
Moderna (Nasdaq: MRNA) released updates on its COVID-19 Vaccine program, highlighting progress in variant-specific booster candidates mRNA-1273.351 and mRNA-1273.211, which show increased neutralizing titers against concerning SARS-CoV-2 variants. Approximately 132 million doses have been delivered globally, with efficacy rates exceeding 90% for all COVID-19 cases and over 95% for severe cases. The company is running multiple studies, including the Phase 2/3 TeenCOVE and KidCOVE studies, while also reporting no association between its vaccine and cerebral venous sinus thrombosis after administering over 64.5 million doses.
Moderna (Nasdaq: MRNA) has announced that David Meline, CFO, and Lavina Talukdar, SVP of Investor Relations, will engage in a fireside chat at the 20th Annual Needham Virtual Healthcare Conference on April 15, 2021, at 11:45 a.m. ET. The event will be accessible via a live webcast on Moderna's investor website, with a replay available for 30 days after the presentation.
Over the past decade, Moderna has evolved from an mRNA research stage entity into a leader in mRNA therapeutics and vaccines, currently advancing 24 development programs across various medical fields.
Moderna, Inc. (Nasdaq: MRNA) announced the publication of data in The New England Journal of Medicine showcasing the persistent antibody response achieved by its COVID-19 vaccine six months post-second dose. The study involved 33 participants from a Phase 1 trial, confirming robust antibody levels, aligning with prior findings on natural COVID-19 immunity. Ongoing studies will further evaluate immune responses. Moderna is also advancing its clinical strategy to combat emerging variants and enhance vaccine efficacy as part of its commitment to addressing the pandemic.
Moderna and Catalent have expanded their strategic collaboration, dedicating a new high-speed vial filling line at Catalent's Bloomington facility for the production of the Moderna COVID-19 Vaccine. This expansion follows a successful milestone of 100 million doses achieved in March 2021. The new line will support not only the COVID-19 vaccine but also other investigational programs in Moderna's pipeline until June 2023. Catalent's investment of $50 million will enhance manufacturing capabilities and expedite project timelines.